Mostrando 5,221 - 5,240 Resultados de 5,896 Para Buscar 'Asentiú~', tiempo de consulta: 1.50s Limitar resultados
  1. 5221
  2. 5222
  3. 5223
  4. 5224
  5. 5225
  6. 5226
  7. 5227
  8. 5228
    “…. – Therapy: Laparoscopic CCE including careful exploration of upper abdominal cavity for KMS manifestation (with no revision of bile duct) and peritoneal adhesiolysis (histological finding, chronic fibrosing cholecystitis with thickening of the wall of the gall bladder but no hint of malignancy) under perioperative prophylaxis with antibiotics and temporary cessation of platelet medication for 7 d preoperatively, “bridging” with low molecular weight heparin (Clexane, 1 × 40 mg s.c.; Sanofi-Aventis, Frankfurt/Main, Germany); 1 h preoperatively, 15–20 mg/kg body weight Cyclocapron i.v. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 5229
  10. 5230
  11. 5231
  12. 5232
  13. 5233
    “…RESULTS: Microcystin-LR induced the phosphorylation and accumulation of p53 in HEK293-OATP1B3 cells, which resulted in up-regulation of the expression of p53 transcript targets, including p21 and seven in absentia homolog 1 (siah-1). In addition, microcystin-LR activated Akt signaling through the phosphorylation of Akt and glycogen synthase kinase 3β. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  14. 5234
  15. 5235
  16. 5236
  17. 5237
  18. 5238
  19. 5239
    “…Currently there are no JAK-STAT pathway inhibitors in clinical trials for GBM, so we sought to examine the anti-GBM activity of SAR317461 (Sanofi-Aventis), a newer generation, highly potent JAK2 inhibitor that exhibits low toxicity and good pharmacokinetics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 5240
Herramientas de búsqueda: RSS